Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 5/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945209 | 0.84 | MAOB (0.39) | IDO1JAK2MAOBIKBKE | |
| SCHEMBL21945216 | 0.84 | MAOB (0.39) | IDO1JAK2MAOBIKBKE | |
| SCHEMBL21945116 | 0.83 | POLB (0.31) | ADORA2AADORA1 | |
| SCHEMBL23339777 | 0.82 | PGR (0.43) | NOTUMIDO1JAK2TAAR1PGR | |
| SCHEMBL21945244 | 0.82 | POLB (0.33) | ADORA2AADORA1 | |
| SCHEMBL21944787 | 0.80 | SMPD1 (0.41) | ALOX5MAOB | |
| SCHEMBL21945246 | 0.80 | ESR1 (0.38) | NOTUMESR2ALOX5ADORA2AADORA1 | |
| SCHEMBL21944761 | 0.79 | NOTUM (0.35) | NOTUMPGR | |
| SCHEMBL21945229 | 0.77 | LTA4H (0.39) | MAOB | |
| SCHEMBL21944755 | 0.77 | KDM1A (0.32) | PGRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | NOTUM 1379/4885IDO1 2430/4885JAK2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.